Skip to main content
logo
BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ: BLSM · Real-Time Price · USD
23.12
-2.13 (-8.44%)
Sep 23, 2026, 10:58 AM EDT - Market open

BlossomHill Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
--60.56-30.7
Depreciation & Amortization
-0.440.35
Stock-Based Compensation
-1.090.5
Other Operating Activities
-1.290.7
Change in Accounts Payable
-1.47-1.14
Change in Other Net Operating Assets
-9.35-1.13
Operating Cash Flow
--46.93-31.42
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
--1.07-0.09
Investing Cash Flow
--1.07-0.09

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Issuance of Common Stock
-0.590.42
Financing Cash Flow
-84.5317.56

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
-36.54-13.95

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
--47.99-31.51
Free Cash Flow Growth
---
Free Cash Flow Per Share
--19.68-13.76
Levered Free Cash Flow
--28.44-
Unlevered Free Cash Flow
--28.44-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
-10.81-2.27
SEC Filings: 10-K · 10-Q